An observational study in Intrahepatic Cholangiocarcinoma (Icc), sponsored by First Affiliated Hospital, Sun Yat-Sen University. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by First Affiliated Hospital, Sun Yat-Sen University · Observational
The aim of this observational study was to understand the prognostic imaging of the degree of intratumoral fibrosis and intratumoral α-SMA levels in patients with intrahepatic cholangiocarcinoma (ICC). The main questions it aims to answer are:
Whether the degree of intratumoral fibrosis and the level of intratumoral α-SMA affect the overall survival and progression-free survival of ICC patients.
Participants will be surveyed for survival and tumor recurrence up to 5 years after surgery.
Intrahepatic cholangiocarcinoma (ICC), which originates from the proximal secondary bile duct in the liver parenchyma (based on the direction of bile flow), is the second most common type of primary liver cancer after hepatocellular carcinoma, accounting for 10-20% of all primary liver cancers. In recent years, the incidence and mortality of ICC have been increasing in most regions of the world. α-SMA-positive CAFs in ICC may aggravate tumor progression and reduce survival time, which is a significant prognostic indicator. However, the evaluation of α-SMA expression level in previous studies mostly relied on subjective evaluation by pathologists after visual observation, and there was a lack of quantitative indicators. In addition, there are differences in the effect of intratumoral fibrosis on the prognosis of ICC, and there may be an interactive relationship between the expression of α-SMA and intratumoral fibrosis. The effect of intratumoral α-SMA expression level and fibrosis on the prognosis of ICC still deserves further exploration. Therefore, the aim of this study is to investigate the relationship between the expression level of α-SMA and the degree of fibrosis in ICC and Progression-free survival (PFS) and Overall survival (OS) by survival analysis. To determine the expression level of α-SMA and the risk degree of fibrosis in ICC.
914 studies on the registry are indexed under Cholangiocarcinoma; 286 are open to participants now.
This study's enrollment of 169 is below the median of 196 across 176 observational studies indexed under Cholangiocarcinoma.
Browse Cholangiocarcinoma studies →First Affiliated Hospital, Sun Yat-Sen University is the lead sponsor of 155 studies on the registry; 51 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with single ICC who underwent radical partial hepatectomy in our hospital from January 2018 to January 2024 were retrospectively enrolled in this study.
Exclusion Criteria:
Other: No Interventions
Other: No Interventions
Other: No Interventions
Other: No Interventions
Only the degree of intratumoral fibrosis and the expression of α-SMA in the postoperative pathological specimens of ICC patients were observed, without intervention measures.
Treatment Effects
5-year overall survival (OS)
Time frame: From the time of the patient's surgery to the end of the 5-year follow-up
Plan to share: Undecided — All primary data are available from the corresponding author upon reasonable request.
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital, Sun Yat-Sen University